Abstract
Previous preclinical and clinical trials have shown promising antitumour activity and toxicity profile when employing the ‘Synergy between Immunotherapy and Radiotherapy’ (SITAR) strategy. Approximately, one in seven radiation therapy studies currently recruiting is investigating SITAR. This article reviews the range of cancers known to respond to immunotherapy and publications analysing SITAR. It sets the background for work that needs to be done in future clinical trials. It also reviews the potential toxicities of immunotherapy and discusses areas where caution is required when combining treatments.
| Original language | English |
|---|---|
| Pages (from-to) | 881-895 |
| Number of pages | 15 |
| Journal | Journal of Medical Imaging and Radiation Oncology |
| Volume | 66 |
| Issue number | 6 |
| Early online date | 14 Jun 2022 |
| DOIs | |
| Publication status | Published - Sept 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Clinical evidence for synergy between immunotherapy and radiotherapy ( SITAR )'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver